Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: BIOLOGICAL: Trastuzumab|DRUG: Alpelisib|DRUG: Fulvestrant|DRUG: Vinorelbine|DRUG: Capecitabine|DRUG: Eribulin
Sponsor: Spanish Breast Cancer Research Group
Collaborators: ETOP IBCSG Partners Foundation|Breast International Group|Novartis Pharmaceuticals